Atea Pharmaceuticals Secures $200M Hercules Facility to Extend Cash Runway into Mid-2028
Atea Pharmaceuticals (AVIR) has announced a significant financial milestone by securing a $200 million Hercules facility. This capital injection is intended to extend the company's cash runway through mid-2028, providing stability as it advances its clinical pipeline. The company is currently focusing on several key developmental milestones, most notably targeting a New Drug Application (NDA) for its Hepatitis C Virus (HCV) program in mid-2027. Management expressed optimism regarding recent progress, particularly noting the performance of the C-BEYOND study as they prepare for a high-activity period in 2027.
Topics: clinical development pipeline progress quarterly results